Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  gemtuzumab ozogamicin
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-11 of 11 for your search:
Start Over
Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 61 and over
Sponsor: Other
Protocol IDs: EORTC-06031, NCT00091234
Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations
Phase: Phase III
Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment
Status: Approved-not yet active
Age: 60 and over
Sponsor: Other
Protocol IDs: AML18, NCT02272478
Gemtuzumab Ozogamicin Before Allogeneic Stem Cell Transplantation
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: EK 92062003, NCT00460447
Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: 07-154, NCT00660036
Fludarabine, Cytarabine, Filgrastim and Idarubicin in Core Binding Factor (CBF) Leukemias
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2007-0147, NCI-2012-01659, NCT00801489
Vorinostat Combined With Gemtuzumab Ozogamicin, Idarubicin and Cytarabine in Acute Myeloid Leukemia
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 50 and over
Sponsor: Other
Protocol IDs: 2009-08-029, NCT01039363
Acute Promyelocytic Leukemia (APL) Treated With ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin
Phase: Phase II
Type: Treatment
Status: Active
Age: 10 and over
Sponsor: Other
Protocol IDs: 2010-0981, NCI-2011-02767, NCT01409161
SCT Plus Immune Therapy in Average Risk AML/MDS
Phase: Phase II
Type: Treatment
Status: Active
Age: 30 and under
Sponsor: Other
Protocol IDs: NYMC-504, L 10,394, NCT02117297
Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS
Phase: Phase II
Type: Treatment
Status: Active
Age: 30 and under
Sponsor: Other
Protocol IDs: NYMC-515, L-10,349, NCT02221310
Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 3 months and over
Sponsor: NCI, Other
Protocol IDs: CCCWFU# 99213, NCI-2013-00965, P30CA012197, NCT01869803
Start Over